Evidence map›Paper›PMID 42656337›Full record

ArticleFrontiers in oncology2026

Marta Guariglia, Gian Paolo Caviglia, Silvia Gaia, Chiara Rosso, Emanuela Rolle, Francesca Saba, Eleonora Dileo, Gemma Martina Silvestri, Angelo Armandi, Patrizia Carucci and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marta GuarigliaDepartment of Medical Sciences, University of Torino, Turin, Italy.
Gian Paolo CavigliaDepartment of Medical Sciences, University of Torino, Turin, Italy.
Silvia GaiaGastroenterology Unit, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy.
Chiara RossoDepartment of Medical Sciences, University of Torino, Turin, Italy.
Emanuela RolleGastroenterology Unit, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy.
Francesca SabaDepartment of Medical Sciences, University of Torino, Turin, Italy.
Eleonora DileoDepartment of Medical Sciences, University of Torino, Turin, Italy.
Gemma Martina SilvestriDepartment of Medical Sciences, University of Torino, Turin, Italy.
Angelo ArmandiDepartment of Medical Sciences, University of Torino, Turin, Italy.
Patrizia CarucciGastroenterology Unit, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy.
Elisabetta BugianesiDepartment of Medical Sciences, University of Torino, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Genetic variants involved in lipid and glucose metabolism have been implicated in liver disease progression and hepatocellular carcinoma (HCC) development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, their prognostic role in patients with established HCC remains unclear. We aimed to investigate the association between MASLD-related genetic variants and overall survival (OS) in patients with MASLD-related HCC. Methods: We retrospectively evaluated 258 patients with MASLD-related HCC (median age: 73, 49-79 years; male sex: 86.8%); most patients had a diagnosis of early tumor (BCLC 0/A: n = 162; 62.8%). Results: Among the investigated gene variants, only the Conclusions:

Indexed as

HCCmetabolic dysfunction-associated steatotic liver diseaseoverall survivalprognosissingle nucelotide polymorphisms

Identifiers

PMID42656337
PMCPMC13506385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.